Celebrating the progression of treatment for Inherited Retinal Diseases on Rare Disease Day

Video

Dr Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

On Rare Disease Day, Dr Aleksandra Rachitskaya talks about how far treatment has come for Inherited Retinal Diseases. Once an untreatable diagnosis, Inherited Retinal Diseases now have an approved gene therapy option as well as more therapeutics under investigation.

Video transcript

Dr Rachitskaya: Hi, my name is Aleksandra Rachitskaya, and I'm a retina surgeon at Cleveland Clinic Cole Eye Institute. On this Rare Disease Day, I'm really excited about the future of Inherited Retinal Diseases. It used to be that Inherited Retinal Diseases were a type of diagnosis one was given, and there was not much hope in terms of treatment. A lot of patients would progressively lose vision and had to rely on low vision devices.

But these days, we do have an approved gene therapy, and also a lot of clinical trials focusing on gene therapy for a variety of Inherited Retinal Diseases. So on this Rare Disease Day, I think the future of Inherited Retinal Diseases as it comes to gene therapy is bright, and I'm excited to be part of that.

Note: This transcript has been lightly edited for clarity.

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Related Content
© 2024 MJH Life Sciences

All rights reserved.